Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece.

Kourlaba, G; Boukovinas, I; Saridaki, Z; Papagiannopoulou, V; Tritaki, G; Maniadakis, N

Kourlaba, G; Boukovinas, I; Saridaki, Z; Papagiannopoulou, V; Tritaki, G; Maniadakis, N.

Affiliation

Kourlaba G; National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Boukovinas I; Bioclinic Thessaloniki - Oncology Unit, Thesaloniki, Greece.
Saridaki Z; Laboratory of Tumor Cell Biology School of Medicine-University of Crete, Herakleion, Crete, Greece.
Papagiannopoulou V; AMGEN Hellas, Marousi, Greece.
Tritaki G; AMGEN Hellas, Marousi, Greece.
Maniadakis N; National School of Public Health, Athens, Greece.

Value Health ; 17(7): A633, 2014 Nov.

Article in En | MEDLINE | ID: mdl-27202252

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Grecia Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google